Review article · 2022
Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs
Journal of Pharmaceutical Sciences, 111(4), 960–969 · Published 2 February 2022 · DOI 10.1016/j.xphs.2022.01.032
In brief
“Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs” is a 2022 review article by Vibha Jawa and 4 co-authors, published in Journal of Pharmaceutical Sciences. OpenAlex counts 23 citations as of 20 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 23
- Most cited in
- 2025 (8)
- Field-weighted impact
- 0.37
- References
- 61
- Authors
- 5
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022). Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs. Journal of Pharmaceutical Sciences, 111(4), 960–969. https://doi.org/10.1016/j.xphs.2022.01.032
MLA 9
Jawa, Vibha, et al. “Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.” Journal of Pharmaceutical Sciences, vol. 111, no. 4, 2022, pp. 960–969. https://doi.org/10.1016/j.xphs.2022.01.032.
Chicago
Jawa, Vibha, Jad Maamary, Michael D. Swanson, Shuli Zhang, and Diana L. Montgomery. 2022. “Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.” Journal of Pharmaceutical Sciences 111 (4): 960–969. https://doi.org/10.1016/j.xphs.2022.01.032.
Harvard
Jawa, V. et al. (2022) ‘Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs’, Journal of Pharmaceutical Sciences, 111(4), pp. 960–969. doi:10.1016/j.xphs.2022.01.032.
IEEE
V. Jawa, J. Maamary, M. D. Swanson, S. Zhang, and D. L. Montgomery, “Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs,” Journal of Pharmaceutical Sciences, vol. 111, no. 4, pp. 960–969, 2022, doi: 10.1016/j.xphs.2022.01.032.
BibTeX
@article{jawa2022implementing,
title = {{Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs}},
author = {Jawa, Vibha and Maamary, Jad and Swanson, Michael D. and Zhang, Shuli and Montgomery, Diana L.},
journal = {Journal of Pharmaceutical Sciences},
year = {2022},
volume = {111},
number = {4},
pages = {960--969},
doi = {10.1016/j.xphs.2022.01.032},
url = {https://doi.org/10.1016/j.xphs.2022.01.032}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 4 | |
| 2024 | 2 | |
| 2025 | 8 | |
| 2026 | 8 |
Its field-weighted citation impact is 0.37: it has been cited 0.37 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- immunogenicity
- biologics
- risk mitigation
- quality by design
- risk score
- pharmacogenomics
- regulatory submissions
- Investigational New Drug application
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022). Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs. Journal of Pharmaceutical Sciences, 111(4), 960–969. https://doi.org/10.1016/j.xphs.2022.01.032
How many times has this paper been cited?
23 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Vibha Jawa, Jad Maamary, Michael D. Swanson, Shuli Zhang, Diana L. Montgomery.
What is the DOI of this paper?
10.1016/j.xphs.2022.01.032, permanently at https://doi.org/10.1016/j.xphs.2022.01.032. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.